

Principles of Working with the Pharmaceutical Industry:

The Canadian Association of Psoriasis Patient (CAPP) is proud to work with a variety of funders, all with the goal to improve the quality of life for Canadians living with psoriasis and psoriatic arthritis. This includes many pharmaceutical companies that play the crucial role of bringing new treatments for psoriatic diseases to the market.

Recognizing the value that pharmaceuticals bring to skin patients and to avoid conflicts of interest, CAPP follows guiding principles with regards to interactions with the pharmaceutical industry:

- CAPP welcomes the opportunity to partner with pharmaceutical companies, with honesty, transparency and accountability at the core of all relationships.
- We will always put the best interests of people living with psoriasis and psoriatic arthritis first.
- CAPP will be transparent about its relationship(s) with pharmaceutical companies to all stakeholders and list all funders on our website.
- We believe that patients should be informed about all treatment options and will endeavour to do so, but we will not endorse any specific medication or course of treatment.
- CAPP accepts funds from pharmaceutical companies provided that there is an agreement about the nature of the funding and that CAPP owns any and all intellectual property. The company will not influence directly or indirectly any content or communications as a result of funding.